4-Mar-2026 3:05 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwoods fireside chat will be accessible through the Investors & Media section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwoods website following the conference. About Ironwood Pharmaceuticals
25-Feb-2026 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing lifechanging therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and fullyear 2025 results and recent business performance. In 2025, LINZESS delivered 11% EUTRx demand growth year-over-year, continuing to strengthen its position as the prescription market leader for the treatment of IBS-C and CIC, surpassing 5.7
18-Feb-2026 3:21 PM CST - Business Wire Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section o
10-Nov-2025 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance. LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand growth combined with improved net pricing, which prompted us to raise our full-year 2025 financ
7-Aug-2025 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance. In the second quarter, LINZESS delivered $248 million in U.S. net sales with robust EUTRx demand growth of 10% year-over-year. Additionally, LINZESS net price was in-line with our expectations for the qu
7-May-2025 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports First Quarter 2025 Results Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st
30-Apr-2025 3:25 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwoods fireside chat will be accessible through the Investors section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwoods website following the conference. About Ironwood
27-Feb-2025 6:00 AM CST - Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results and recent business performance. We believe that 2025 marks the beginning of a transformation for Ironwood that will lay the foundation for growth, long-term value creation, and the delivery of new medicines to rare diseas
20-Feb-2025 3:00 PM CST - Business Wire Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwoods w
4-Mar-2026 3:05 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, March 11th at 4:00 p.m. ET. A live webcast of Ironwoods fireside chat will be accessible through the Investors & Media section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwoods website following the conference. About Ironwood Pharmaceuticals
25-Feb-2026 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing lifechanging therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and fullyear 2025 results and recent business performance. In 2025, LINZESS delivered 11% EUTRx demand growth year-over-year, continuing to strengthen its position as the prescription market leader for the treatment of IBS-C and CIC, surpassing 5.7
18-Feb-2026 3:21 PM CST - Business Wire Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section o
10-Nov-2025 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance. LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand growth combined with improved net pricing, which prompted us to raise our full-year 2025 financ
7-Aug-2025 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance. In the second quarter, LINZESS delivered $248 million in U.S. net sales with robust EUTRx demand growth of 10% year-over-year. Additionally, LINZESS net price was in-line with our expectations for the qu
7-May-2025 6:05 AM CST - Business Wire Ironwood Pharmaceuticals Reports First Quarter 2025 Results Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st
30-Apr-2025 3:25 PM CST - Business Wire Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwoods fireside chat will be accessible through the Investors section of the companys website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwoods website following the conference. About Ironwood
27-Feb-2025 6:00 AM CST - Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full year 2024 results and recent business performance. We believe that 2025 marks the beginning of a transformation for Ironwood that will lay the foundation for growth, long-term value creation, and the delivery of new medicines to rare diseas
20-Feb-2025 3:00 PM CST - Business Wire Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwoods w
